NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice
CompletedN/A
Sponsor: Pfizer
Conditions: Renal Cell Carcinoma
This is a post-marketing Surveillance study to observe INLYTA® treatment dosing pattern, safety and effectiveness in Taiwan real world routine practice. The primary objective of this registry is to monitor the dose adjustment of INLYTA® in real world routine practice. The secondary objectives include safety profile, objective response rate, and progression-free rate in real world routine practice.
Eligibility overview
Sex: ALL
Age: 18 Years to 85 Years
Healthy volunteers: No
Study type: OBSERVATIONAL
Eligibility criteria
Inclusion Criteria: * Patients diagnosed as advanced RCC by histology or cytology * Patients using axitinib as therapy after failure of sunitinib or cytokine * Patients received axitinib treatment and follow up in the health care center participating present registry * Patients agree to participate and signed inform consent or IRB waiving of signed informed consent document is available Exclusion Criteria: * Patients with first dose of axitinib earlier than 7th May 2013 * Patients with first dose of axitinib later than 30th June 2015. * Patients participating in clinical research involving axitinib * Patients with hypersensitivity to axitinib or to any other component of axitinib * Patients under 18-year of age * Pregnant women.